SCHEMBL3671813

SCHEMBL3671813

COc1ccccc1CNC(=O)c1cc(-c2ccc3[nH]ncc3c2)on1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 5/20 0.62
PIM1 P11309 1/20 0.62
GSK3B P49841 1/20 0.62
HPGD P15428 5/20 0.56
HSD17B10 Q99714 5/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
CYP1A2 P05177 2/20 0.52
CYP3A4 P08684 1/20 0.52
PKM P14618 1/20 0.52
CYP2C19 P33261 1/20 0.52
ROCK1 Q13464 2/20 0.51
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
NPSR1 Q6W5P4 3/20 0.50
LMNA P02545 2/20 0.50
MAPT P10636 4/20 0.49
SCD5 Q86SK9 1/20 0.49
DYRK1A Q13627 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666554 0.86 ROCK2 (0.62) ROCK2PIM1GSK3BHPGDKMT2A
SCHEMBL3636127 0.85 ROCK2 (0.61) ROCK2PIM1GSK3BHPGDHSD17B10
SCHEMBL13902052 0.84 STAT3 (0.67) ROCK2PIM1GSK3BHPGDHSD17B10
SCHEMBL3670364 0.83 ROCK2 (0.67) ROCK2PIM1GSK3BHPGDHSD17B10
SCHEMBL3640238 0.83 ROCK2 (0.59) ROCK2PIM1GSK3BMEN1KMT2A
SCHEMBL29378299 0.82 HSD17B10 (0.65) HPGDHSD17B10MEN1KMT2AALDH1A1
SCHEMBL4298374 0.81 ROCK2 (0.62) ROCK2PIM1GSK3BHPGDHSD17B10
SCHEMBL3636001 0.81 ROCK2 (0.71) ROCK2PIM1GSK3BHPGDHSD17B10
SCHEMBL5412630 0.81 ROCK2 (0.64) ROCK2HPGDMEN1KMT2AROCK1
SCHEMBL3632716 0.81 ROCK2 (0.59) ROCK2PIM1GSK3BHPGDROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885PIM1 11/4885GSK3B 1/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885PIM1 11/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.